Real-time morphometric analysis of targeted therapy for neuroblastoma cells in monolayer and 3D hydrogels using digital holographic microscopy.

Fecha de publicación: Fecha Ahead of Print:

Autores de INCLIVA

Grupos y Plataformas de I+D+i

Abstract

High-risk neuroblastoma (HR-NB) patient treatment is currently insufficient and challenging due to its high clinical, morphological, and genetic heterogeneity as well as the scarcity of available samples for research. We used a gelatin- and silk fibroin-based hydrogel system with cross-linked vitronectin (VN) as an artificial biomimetic three-dimensional (3D) environment to mirror aggressive neuroblastoma (NB) tumors and tested long-term cell response to Cilengitide (CLG). Based on our previous studies and others using the integrin inhibitor CLG as a potential mechanotherapy drug, we show that CLG caused cell detachment in monolayer cultures of MYCN-amplified SK-N-BE (2) and ALK-mutated SH-SY5Y human neuroblastoma cell lines. Cell detachment and aggregation were maintained in hydrogel-free monolayer cells whereas cells embedded in hydrogels presented different responses to treatment, suggesting differential anoikis resistance between the two cell lines. This underscores the advantages of testing therapeutic approaches using real-time imaging of tumor cells in 3D biomimetic models and its contribution to precision medicine.

© 2024 The Authors.

Datos de la publicación

ISSN/ISSNe:
2589-0042, 2589-0042

Iscience  CELL PRESS

Tipo:
Article
Páginas:
111231-111231
PubMed:
39569369

Citas Recibidas en Web of Science: 1

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Cancer; Cell biology; Mechanobiology; Methodology in biological sciences

Campos de Estudio

Financiación

Proyectos y Estudios Clínicos

INCORPORACIÓN DE NUEVAS ÁREAS TEMÁTICAS Y NUEVOS GRUPOS AL CONSORCIO CIBER

Investigador Principal: ROSA NOGUERA SALVA

CB16/12/00484 . INSTITUTO SALUD CARLOS III

Neuroblastoma: estrategias mecanoterapéuticas basadas en modelos 3D y tumores derivados de pacientes con microambiente rico en vitronectina

Investigador Principal: ROSA NOGUERA SALVA

PI20/01107 . INSTITUTO SALUD CARLOS III . 2021

Cita

Compartir